Table 2 Genes identified through mutational analysis in AML in the total, M2, and M3 subtype patient groups

 NEFH

22

In Frame Ins(6)/Del(4)

6.27 × 10^-13c

1.18 × 10⁻⁸

RCC [23], ESCC [24]

 TMPRSS13

11

In Frame Del(6), Missense(5)

1.40 × 10^-10c

1.32 × 10⁻⁶

 KRTAP4-5

17

In Frame Ins(5), Missense(1)

5.07 × 10^-8c

3.19 × 10⁻⁴

 OR2T35

1

Frame Shift Ins(1)/Del(4)

1.50 × 10^-7c

7.09 × 10⁻⁴

 HAVCR1

5

Intron SNV(1), In Frame Del(5), Silent(1)

3.62 × 10^-7c

1.37 × 10⁻³

Colorectal [25], RCC [26]

 IFI27

14

In Frame Ins(3)

6.88 × 10^-6c

0.02

Ovarian [27], Breast [28]

 PCSK5

9

Intron SNV(1), Frame Shift Del(6), 3′UTR Ins(7)/Del(1)

8.50 × 10^-6c

0.02

Lung [29]

 GPRIN1

5

Missense(1), In Frame Del(5)

8.88 × 10^-6c

0.02

 MRPL18

6

In Frame Del(3)

2.09 × 10⁻⁵

0.04

 ARSD

X

Intron Ins(2)/Del(2), In Frame Del(4)

2.93 × 10⁻⁵

0.05

CLL [30]

 MAML3

4

In Frame Ins(2)/Del(4), Silent(3), Intron Del(1)

3.33 × 10⁻⁵

0.05

 CEBPA

19

In Frame Ins(3)

5.22 × 10⁻⁵

0.49

HCC [31], AML [32]

 EP400

12

Intron Del(1), In Frame Ins(4)/Del(1)

3.45 × 10⁻⁴

1

RCC [33], Colorectal [34]

 ATXN3

14

In Frame Ins(2), Intron Ins(1)

9.75 × 10⁻⁴

1

Lung [35]